

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patient and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspito.gov

			-	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/855,402	05/13/1997	CHRISTOPHER BRADFIELD		1652
32116 75	590 06/26/2003			
WOOD, PHILLIPS, KATZ, CLARK & MORTIMER 500 W. MADISON STREET SUITE 3800			EXAMINER	
			ULM, JOHN D	
CHICAGO, IL 60661			ART UNIT	PAPER NUMBER
			1646 DATE MAILED: 06/26/2003	37

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 08/855,402

Applicant(s)

. . .

Bradfield et al.

Examiner

John Ulm

Art Unit 1646



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply	•			
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE3 MONTH(S) FROM			
- Extens	tions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
-	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	he statutory minimum of thirty (30) days will be considered timely.			
- If NO p		and will expire SIX (6) MONTHS from the mailing date of this communication.			
- Any re	ply received by the Office later than three months after the mailing date of t patent term adjustment. See 37 CFR 1.704(b).	· · · · · · · · · · · · · · · · · · ·			
Status	poor com aspectation of the control				
. 1) 💢	Responsive to communication(s) filed on Jun 9, 20				
2a) 🗌	This action is FINAL . 2b) 💢 This act	tion is non-final.			
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposit	Disposition of Claims				
4) 💢	Claim(s) 21	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
	Claim(s)				
	Claim(s) 21				
	Claim(s)				
		are subject to restriction and/or election requirement.			
	tion Papers				
9) The specification is objected to by the Examiner.					
10) 🗌	The drawing(s) filed on is/are	e a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)	The proposed drawing correction filed on	is: a) approved b) disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t				
12)	The oath or declaration is objected to by the Exami	iner.			
•	under 35 U.S.C. §§ 119 and 120				
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some* c) None of:					
•	1. \square Certified copies of the priority documents have	e been received.			
2	2. \square Certified copies of the priority documents have	e been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
_	ee the attached detailed Office action for a list of the	e certified copies not received.			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
a) The translation of the foreign language provisional application has been received.					
	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachme		_			
	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s).			
	5) Notice of Informal Patent Application (PTO-152) 6) Other:				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:					

Application/Control Number: 08/855,402 Page 2

Art Unit: 1646

1) Claim 21 is pending in the instant application. Claim 21 has been amended as requested by Applicant in Paper Number 36, filed 09 June of 2003.

- A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09 June of 2003 has been entered.
- 3) Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 4) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- The drawings in the instant application do not comply with 37 C.F.R. § 1.821(d), which requires a reference to a particular sequence identifier (SEQ ID NO:) be made in the specification and claims wherever a reference is made to that sequence. M.P.E.P. 2422.02 expressly states that "when a sequence is presented in a drawing, regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and the sequence identifier ("SEQ ID NO:X") must be used, either in the drawing or in the Brief Description of the Drawings". Correction is required.
- 6 & 7) Claim 21 stands rejected under 35 U.S.C. 102(a) as being clearly anticipated by the Ema et al. publication (BIOCHEM. BIOPHYS. RES. COMM. 184(1):246-253, 15 Apr. 1992)

Application/Control Number: 08/855,402 Page 3

Art Unit: 1646

and under 35 U.S.C. 102(b) as being clearly anticipated by the Bradfield et al. publication (MOLECULAR PHARMACOLOGY 39(1):13-19, 1991) for those reasons of record in section "5 & 6" of Paper Number 29. Essentially as stated therein, Figure 1c of the Ema et al. publication provided a written description of the complete amino acid sequence of an isolated murine Ah receptor prior to the filing of the instant application. The Bradfield et al. publication clearly described an isolated murine liver Ah receptor more than one year before the filing on the instant application. The amino acid sequence presented in SEQ ID NO:37 of the instant application is identical to the amino acid sequence presented as residues 12 to 83 in Figure 1c of Ema et al. Consequently, Figure 1c of Ema et al. described an isolated protein "comprising an amino acid sequence of SEQ ID NO:37" as required by the instant claims. The text in the first full paragraph on page 247 of the Ema et al. publication states that the cDNA described therein encodes the "putative ligand-binding subunit of the Ah receptor" whose purification to homogeneity was described in the Bradfield et al. publication which is identified therein as reference number 11. In the absence of evidence to the contrary, one of would have to reasonably conclude that the purified murine Ah receptor of Bradfield et al. was also a protein "comprising an amino acid sequence of SEQ ID NO:37". Therefore the instant claim encompasses the murine Ah receptor protein that was described in each of these references.

8) Applicant's arguments filed 09 June of 2003 have been fully considered but they are not persuasive.

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER -GROUP 1800